• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

7 New Drugs for Primary Care: Q2 2019

Slideshow

The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about? Click through to find out. 

At the close of the second quarter, Patient Care has compiled a list of 7 new FDA-approved drugs for conditions that are often seen in primary care. Below you will find details on the first generic version of Narcan®--naloxone hydrochloride nasal spray for opioid overdose; the first and only topical lotion that combines halobetasol propionate and tazarotene for the treatment of plaque psoriasis; plus 5 more.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Elevated Lp(a) Level Raises ASCVD Risk Regardless of Age, Sex, Race/Ethnicity: Daily Dose / image credit: ©New Africa/AdobeStock

Elevated Lp(a) Level Raises ASCVD Risk Regardless of Age, Sex, Race/Ethnicity: Daily Dose

April 24th 2024
Article

Your daily dose of the clinical news you may have missed.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

ACP issues guidelines on newer pharmacologic treatment for adults with type 2 diabetes/ image credit: medication pens:©felipecaparros/stock.adobe.com

ACP Recommends SGLT2i, GLP1 RA After Metformin to Manage Cardiorenal Comorbidities in Adults with Type 2 Diabetes

April 22nd 2024
Article

Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Navigating the New Wave of Antiobesity Medications: What Primary Care Clinicians Should Know / Image credit: ©Antonio Diaz/AdobeStock

Navigating the New Wave of Antiobesity Medications: What Primary Care Clinicians Should Know

April 17th 2024
Article

With the rise in demand for newer antiobesity medications, clinicians may face more questions from patients. Here, a primer on the drawbacks and benefits to keep in mind.

Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Regulatory Submission / image credit obese man asleep / ©motortion/stock.adobe.com

Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Mid-2024 Regulatory Submission

April 17th 2024
Article

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

© 2024 MJH Life Sciences

All rights reserved.